FindTrial
Sign In

The study on efficacy of Rituximab in new onset Type 1 diabetes mellitus

The study on efficacy of Rituximab in new onset Type 1 diabetes mellitus - Efficacy of RTX in new onset Type 1 DM

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000013622
Enrollment
10
Registered
2014-04-03
Start date
2011-04-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 1 diabetes mellitus

Interventions

Rituximab

Sponsors

University of Occupational and Environmental Health, Japan, First Department of Internal Medicine, School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients diagnosed Type 1 diabetes mellitus within 3 months after onset, and whose capacity for endogenous insulin secretion was retained.

Exclusion criteria

Exclusion criteria: Patients using insulin therapy, those who were or may have been pregnant, and those with severe liver dysfunction (AST and ALT: 3 times the normal levels) were excluded.

Design outcomes

Primary

MeasureTime frame
The rate of change of curve undersurface area of the serum C peptide concentration in the meal load examination 12 months after rituximab administration.—

Countries

Japan

Contacts

Public ContactAkira Kurozumi

University of Occupational and Environmental Health First Department of Internal Medicine, School of Medicine

akira@med.uoeh-u.ac.jp093-603-1611

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026